S-adenosylmethionine (SAM) is a natural metabolite, and recent studies have found that SAM can target P62 and thus inhibit the NF-κB pathway in NSCLC, thus SAM may become a relatively safe adjuvant therapeutic agent (161). The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.